Associate Account Executive, LatchBio

With backgrounds in big tech and data pipelining for the likes of Google and Twitter, the founders of LatchBio implemented their skills for the rapidly evolving world of biotech, taking the weight of biocomputation off the hands of the scientists running the tests. Having closed a Series A funding round in June 2022, the company's switch from big data companies seems to be paying off.

As new discoveries are made, the problem might arise that LatchBio does not evolve its platform to keep up with the wide range of demands and variants in biological research. At the moment though, its platform - and the cost and time savings it delivers to its users - is turning heads.